{"title":"[Effect of Plasma Epstein-Barr Virus Nucleic Acid Loads on the Clinical Features and Prognosis in Adult Secondary Hemophagocytic Lymphohistiocytosis].","authors":"Li-Min Duan, Guang-Li Yin, Tian Tian, Ju-Juan Wang, Xin Gao, Wan-Ying Cheng, Zi-Wei Fang, Hong-Xia Qiu, Ji Xu","doi":"10.19746/j.cnki.issn.1009-2137.2024.04.041","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effect of pre-treatment plasma Epstein-Barr virus (EBV) DNA copy number on the clinical features and prognosis of patients with adult secondary hemophagocytic lymphohistiocytosis(sHLH).</p><p><strong>Methods: </strong>The clinical characteristics, survival rate, and prognostic factors of 171 patients with adult sHLH treated at Jiangsu Province Hospital from June 2017 to January 2022 were retrospectively analyzed in this study. Patients were divided into three groups, including the EBV DNA-negative group(<5.0×10<sup>2</sup> copies/ml), lower EBV-DNA loads group(5.0×10<sup>2</sup>-8.51×10<sup>4</sup> copies/ml), and higher EBV-DNA loads group(>8.51×10<sup>4</sup> copies/ml), according to pre-treatment plasma EBV-DNA copy number. Cox regression model was established for screening prognostic factors. Adult sHLH survival prediction model was constructed and realized through the nomogram based on EBV-DNA load after adjusted the factors affecting survival of etiology and treatment strategy.Concordance index (C-index) and calibration curves were calculated to verify model predictive and discriminatory capacity.</p><p><strong>Results: </strong>Among 171 adult sHLH patients, 84 patients were not infected with EBV (EBV DNA-negative group), and 87 with EBV (EBV DNA-positive group, 48 lower EBV-DNA loads group and 39 higher EBV-DNA loads group). Consistent elevations in the levels of liver enzymes (ALT and AST), LDH, TG, β <sub>2</sub>-microglobulin and ferritin across the increasing of EBV-DNA load (all <i>P</i> <0.05), while the levels of fibrinogen decrease (<i>P</i> <0.001). The median follow-up time was 52 days (range 20-230 days), and 123 patients died. The overall survival (OS) rate of patients in EBV DNA-positive group was lower than that in EBV DNA-negative group (median OS: 40 days <i>vs</i> 118 days, <i>P</i> <0.001). Higher EBV-DNA loads had worse OS (median OS: 24 days <i>vs</i> 45 days <i>vs</i> 118 days, <i>P</i> <0.0001 for trend) compared to lower EBV-DNA loads and EBV DNA-negative group. Multivariate Cox analysis revealed that higher EBV-DNA loads (<i>P</i> =0.005), fibrinogen≤1.5 g/L (<i>P</i> =0.012), ferritin (<i>P</i> =0.041), associated lymphoma (<i>P</i> =0.002), and anti-tumor based strategy (<i>P</i> =0.001) were independent prognostic factors for OS. The C-indexes of 30 day, 90 days, 365 days survival rate were all greater than 0.8 of the nomogram model and calibration curves provided credibility to their predictive capability. Subgroup analysis showed that patients with higher EBV-DNA loads had a significantly worse prognosis in adult sHLH who were women, ferritin>5 000 μg/L, β<sub>2</sub>-microglobulin>7.4 mmol/L and regardless of age, etiologies, HScore points.</p><p><strong>Conclusion: </strong>The EBV-DNA load is a strong and independent predictor for survival in patients with sHLH. The prognostic nomogram based on EBV-DNA loads was dependable and provides a visual tool for evaluating the survival of adult sHLH.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.04.041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To investigate the effect of pre-treatment plasma Epstein-Barr virus (EBV) DNA copy number on the clinical features and prognosis of patients with adult secondary hemophagocytic lymphohistiocytosis(sHLH).
Methods: The clinical characteristics, survival rate, and prognostic factors of 171 patients with adult sHLH treated at Jiangsu Province Hospital from June 2017 to January 2022 were retrospectively analyzed in this study. Patients were divided into three groups, including the EBV DNA-negative group(<5.0×102 copies/ml), lower EBV-DNA loads group(5.0×102-8.51×104 copies/ml), and higher EBV-DNA loads group(>8.51×104 copies/ml), according to pre-treatment plasma EBV-DNA copy number. Cox regression model was established for screening prognostic factors. Adult sHLH survival prediction model was constructed and realized through the nomogram based on EBV-DNA load after adjusted the factors affecting survival of etiology and treatment strategy.Concordance index (C-index) and calibration curves were calculated to verify model predictive and discriminatory capacity.
Results: Among 171 adult sHLH patients, 84 patients were not infected with EBV (EBV DNA-negative group), and 87 with EBV (EBV DNA-positive group, 48 lower EBV-DNA loads group and 39 higher EBV-DNA loads group). Consistent elevations in the levels of liver enzymes (ALT and AST), LDH, TG, β 2-microglobulin and ferritin across the increasing of EBV-DNA load (all P <0.05), while the levels of fibrinogen decrease (P <0.001). The median follow-up time was 52 days (range 20-230 days), and 123 patients died. The overall survival (OS) rate of patients in EBV DNA-positive group was lower than that in EBV DNA-negative group (median OS: 40 days vs 118 days, P <0.001). Higher EBV-DNA loads had worse OS (median OS: 24 days vs 45 days vs 118 days, P <0.0001 for trend) compared to lower EBV-DNA loads and EBV DNA-negative group. Multivariate Cox analysis revealed that higher EBV-DNA loads (P =0.005), fibrinogen≤1.5 g/L (P =0.012), ferritin (P =0.041), associated lymphoma (P =0.002), and anti-tumor based strategy (P =0.001) were independent prognostic factors for OS. The C-indexes of 30 day, 90 days, 365 days survival rate were all greater than 0.8 of the nomogram model and calibration curves provided credibility to their predictive capability. Subgroup analysis showed that patients with higher EBV-DNA loads had a significantly worse prognosis in adult sHLH who were women, ferritin>5 000 μg/L, β2-microglobulin>7.4 mmol/L and regardless of age, etiologies, HScore points.
Conclusion: The EBV-DNA load is a strong and independent predictor for survival in patients with sHLH. The prognostic nomogram based on EBV-DNA loads was dependable and provides a visual tool for evaluating the survival of adult sHLH.
目的研究治疗前血浆EB病毒(EBV)DNA拷贝数对成人继发性嗜血细胞淋巴组织细胞增多症(sHLH)患者临床特征和预后的影响:本研究回顾性分析了2017年6月至2022年1月在江苏省人民医院接受治疗的171例成人sHLH患者的临床特征、生存率和预后因素。根据治疗前血浆EBV-DNA拷贝数将患者分为三组,包括EBV DNA阴性组(2拷贝/ml)、较低EBV-DNA载量组(5.0×102-8.51×104拷贝/ml)和较高EBV-DNA载量组(>8.51×104拷贝/ml)。建立了用于筛选预后因素的 Cox 回归模型。通过计算一致性指数(C-index)和校正曲线来验证模型的预测和鉴别能力:在171例成人sHLH患者中,84例未感染EB病毒(EB病毒DNA阴性组),87例感染EB病毒(EB病毒DNA阳性组,48例EB病毒DNA载量较低组,39例EB病毒DNA载量较高组)。随着 EBV DNA 负载的增加,肝酶(ALT 和 AST)、LDH、TG、β 2-微球蛋白和铁蛋白水平持续升高(均为 P P vs 118 天,P vs 45 天 vs 118 天,P P =0.005)、纤维蛋白原≤1.5 g/L(P=0.012)、铁蛋白(P=0.041)、伴发淋巴瘤(P=0.002)和抗肿瘤策略(P=0.001)是OS的独立预后因素。30天、90天和365天生存率的C指数均大于提名图模型的0.8,校准曲线为其预测能力提供了可信度。亚组分析表明,在女性、铁蛋白>5 000 μg/L、β2-微球蛋白>7.4 mmol/L且年龄、病因、HScore积分均不受限制的成年sHLH患者中,EBV-DNA载量较高的患者预后明显较差:结论:EBV-DNA载量是预测sHLH患者生存期的一个强有力的独立指标。基于EBV-DNA载量的预后提名图是可靠的,它为评估成人sHLH患者的存活率提供了一个直观的工具。